Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...

Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Find the best ChatGPT alternatives in 2025. Compare Perplexity AI, Claude, Gemini, Abacus.ai, and Copilot for research, ...

Vertex Inc. (NASDAQ:VERX) is a technology company that provides enterprise tax technology solutions for the retail, wholesale ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around 75,000 people with cystic fibrosis rely on Vertex Pharmaceuticals to keep ...

Studies reveal that when handwriting automaticity is achieved, it enhances the cognitive and "free-flowing" intellectual ...

Former England captain Owen Farrell speaks exclusively to Sky Sports at Wednesday's BMW PGA Championship Pro-Am at Wentworth, touching on return with Saracens and international future following shock ...